Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes-Reference-Cited by-同舟云学术

Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes

Published:2017-09 Issue:9 Volume:17 Page:575-583.e2
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Shah Jatin J.,Abonour Rafat,Gasparetto Christina,Hardin James W.^ORCID,Toomey Kathleen,Narang Mohit,Srinivasan Shankar,Kitali Amani,Zafar Faiza^ORCID,Flick E. Dawn,Rifkin Robert M.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference63 articles.

1. Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients;Kaya;Int J Hematol,2012

2. Frontline therapy of multiple myeloma;Moreau;Blood,2015

3. Comparison of survival outcomes among cancer patients treated in and out of clinical trials;Unger;J Natl Cancer Inst,2014

4. Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate;Vist;Cochrane Database Syst Rev,2008

5. “Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group;Katodritou;Ann Hematol,2014

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Second Line Therapy in Multiple Myeloma: A SEER Medicare Analysis;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the ConnectⓇ MM Registry;Clinical Lymphoma Myeloma and Leukemia;2024-06

3. Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real‐world setting: The ALFA study;European Journal of Haematology;2024-05-09

4. The establishment of a multiple myeloma clinical registry in the Asia–Pacific region: The Asia–Pacific Myeloma and Related Diseases Registry (APAC MRDR);BMC Medical Research Methodology;2024-05-02

5. Designing and testing treatments for alcohol use disorder;International Review of Neurobiology;2024